Abstract
While the causes of obesity remain elusive, the relationship between obesity and insulin resistance is a well-established fact [1]. Insulin resistance is defined as a smaller than normal response to a certain dose of insulin, and contributes to several pathological problems of obese patients such as hyperlipidemia, arteriosclerosis and hypertension. Several pieces of evidence indicate that the cytokine tumor necrosis factor a (TNF-α) is an important player in the state of insulin resistance observed during obesity. In this review we will try to summarize what is known about the function of TNF-α in insulin resistance during obesity and how TNF-α interferes with insulin signaling. (Mol Cell Biochem 182: 169-175, 1998)
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Sigal RJ, Warram JH: The interaction between obesity and diabetes. Curr Opin Endocrinol Diab 3: 3–9, 1996
Pennica D, Nedwin GE, Hayflick JS, Seeburg PH, Dernick R, Palladino MA, Kohr WJ, Aggarwal BB, Goeddel DV: Human tumor necrosis factor: Precursor structure, expression and homology to lymphotoxin. Nature 312: 724–727, 1984
Gray PW, Aggarwal BB, Benton CV, Bringman TS, Henzel WJ, Jarret JA, Leung DW, Moffat BNP, Svedersky LP, Palladino MA, Nedwin GE: Cloning and expression of cDNA for human lymphotoxin, a lymphokine with tumor necrosis activity. Nature 312: 721–724, 1984
Fiers W: Tumor necrosis factor. FEBS Lett 285: 199–212, 1991
Vassalli P: The pathophysiology of tumor necrosis factors. Annu Rev Immunol 10: 411–452, 1992
Tracey KJ, Cerami A: Tumor necrosis factor, and other cytokines and disease. Annu Rev Cell Biol 9: 317–343, 1993
Vandenabeele P, Declercq W, Beyaert R, Fiers W: Two tumor necrosis factor receptors: Structure and function. Trends Cell Biol 5: 392–399, 1995
Kriegler M, Perez C, DeFay K, Albert I, Lu S: A novel form of TNF/ cachectin is a cell surface cytotoxic transmembrane protein: Ramifications for the complex physiology of TNF. Cell 53: 45–53, 1988
Mohler K, Sleath P, Fitzner J, Cerretti D, Alderson M, Kerwar S, Torrance D, Otten-Evans C, Greenstreet T, Weerawarna K, Al E: Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing. Nature 370: 218–220, 1994
Gearing A, Beckett P, Christodoulou M, Churchill M, Clements J, Davidson A, Drummond A, Galloway W, Gilbert R, Gordon J, Al E: Processing of tumour necrosis factor-alpha precursor by metalloproteinases. Nature 370: 555–558, 1994
Bazzoni F, Beutler B: How do tumor necrosis factor receptors work? J Inflam 45: 221–238, 1995
Tartaglia LA, Weber RF, Figari IS, Reynolds C, Palladino JMA, Goeddel DV: The two different receptors for tumor necrosis factor mediates distinct cellular responses. Proc Natl Acad Sci USA 88: 9292–9296, 1991
Tartaglia L, Pennica P, Goeddel D: Ligand passing: The 75-kDa tumor necrosis factor (TNF) receptor recruits TNF for signaling by the 55-kDa TNF receptor. J Biol Chem 268: 18542–18548, 1993
Rothe M, Wong SC, Henzel WJ, Goeddel DV: A novel family of putative signal transducers associated with the cytoplasmic domain of the 75 kDa tumor necrosis factor receptor. Cell 78: 681–692, 1994
Rothe M, Pan M, Henzel W, Ayres T, Goeddel D: The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins. Cell 83: 1243–1252, 1995
Rothe M, Xiong J, Shu H-B, Williamson K, Goddard A, Goeddel DV: I-TRAF is a novel TRAF-interacting protein that regulates TRAFmediated signal transduction. Proc Natl Acad Sci USA 93: 8241–8246, 1996
Adam-Klages S, Adam D, Wiegman K, Struve S, Kolanus W, Schneider-Mergener J, Kronke M: FAN, a novel WD-repeat protein, couples the p55TNF-receptor to neutral sphingomyelinase. Cell 86: 937–947, 1996
Hsu H, Xiong J, Goeddel D: The TNF receptor 1-associated protein TRADD signals death and NF-KB activation. Cell 81: 495–504, 1995
Hsu H, Shu HB, Pan MG, Goeddel DV: TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signaling transduction pathways. Cell 84: 299–308, 1996
Stanger B, Leder P, Lee T, Kim E, Seed B: RIP: A novel protein containing a death domain that interacts with Fas/APO-1 (CD95) in yeast and causes cell death. Cell 81: 513–523, 1995
Hsu H, Huang J, Shu HB, Baichwal V, Goeddel DV: TNF-dependent recruitment of the protein kinase RIP to the TNF receptor-1 signaling complex. Immunity 4: 387–396, 1996
Boldin MP, Goncharov TM, Goltsev YV, Wallach D: Involvement of MACH, a novel MORTl/FADD-interacting protease, in FAS/APO-1 and TNF receptor induced cell death. Cell 85: 803–815, 1996
Muzio M, Chinnaiyan A, Kischkel F, O’Rourke K, Shevchenko A, Ni J, Scaffidi C, Bretz J, Zhang M, Gentz R, Mann M, Krammer P, Peter M, Dixit V: FLICK, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell 85: 817–827, 1996
Wang C-Y, Mayo MW, Baldwin AS: TNF-and cancer therapy-induced apoptosis: potential by inhibition of NF-KB. Science 274: 784–786, 1996
Beg AA, Baltimore D: An essential role for NF-KB in preventing TNF-α-induced cell death. Science 274: 782–784, 1996
Van Antwerp DJ, Martin SJ, Kafri T, Green DR, Verma IM: Supression of TNFa-induced apoptosis by NF-Kb. Science 274: 787–789, 1996
Liu Z-g, Hsu H, Goeddel DV, Karin M: Dissection of TMF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-KB activation prevents cell death. Cell 87: 565–576, 1996
Van Dongen CJ, Zwiers H, Gispen WH: Purification and partial characterization of the phosphatidylinositol 4-phosphate kinase from rat brain. Biochem J 223: 197–203, 1984
Lang CH, Dobrescu C, Bagby GJ: Tumor necrosis factor impairs insulin action on peripheral glucose disposal and hepatic glucose output. Endocrinology 130: 43–52, 1992
Grunfeld C, Feingold K: The metabolic effect of tumor necrosis factor and other cytokines. Biotherapy 3: 143–158, 1991
Torti FM, Dieckmann B, Beutler B, Cerami A, Ringold GM: A macrophage factor inhibits adipocyte gene expression: An model for cachexia. Science 229: 867–869, 1985
Grunfeld C, Feingold K: Metabolic disturbance and wasting in the acquired immunodeficiency syndrome. N Engl J Med 327: 329–337, 1992
Copeland GP, Leinster SJ, Davis JC, Hipkin LJ: Insulin resistance in patient with colorectal cancer. Br J Surg 74: 1031–1035, 1987
Marano M, Moldawer L, Fong Y, Al E: cachectin/TNF production in experimental burns and pseudonomas infection. Arch Surg 123: 1383–1388, 1988
Hotamisligil GS, Shargill NS, Spiegelman BM: Adipose expression of tumor necrosis factor-a: Direct role in obesity-linked insulin resistance. Science 259: 87–91, 1993
Hofmann C, Lorenz K, Braithwaite SS, Colca JR, Palazuk BJ, Hotamisligil GS, Spiegelman BM: Altered gene expression for tumor necrosis factora and its receptors during drug and dietary modulation of insulin resistance. Endocrinology 134: 264–270, 1994
Lowell BB, Susulic S, Hamann A, Lawitts JA, Himms H-J, Boyer BB, Kozak LP, Flyers JS: Development of obesity in transgenic mice after genetic ablation of brown adipose tissue. Nature 366: 740–742, 1993
Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM: Increased adipose tissue expression of tumor necrosis factor-α in human obesity and insulin resistance. J Clin Invest 95: 2409–2415, 1995
Kern P, Saghizadeh M, Ong J, Bosch R, Deem R, Simsolo R: The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest 95: 2111–2119, 1995
Saghizadeh M, Ong JM, Garvey TW, Henry R, Kern PA: The expression of TNF-α by human muscle. J Clin Invest 97: 1111–1116, 1996
Hotamisligil GS, Budavari A, Murray D, Spiegelman BM: Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes. J Clin Invest 94: 1543–1549, 1994
Hotamisligil GS, Johnson RS, Distel RJ, Ellis R, Papaioannou VE, Spiegelman BM: Uncoupling of obesity from insulin resistance through a targeted mutation in aP2, the adipocyte fatty acid binding protein. Science 274: 1377–1379, 1996
Hotamisligil GS, Murray DL, Choy LN, Spiegelman BM: Tumor necrosis factor a inhibits signaling from the insulin receptor. Proc Natl Acad Sci 91: 4854–4858, 1994
Stephens J, Pekala P: Transcriptional repression of the C/EBP-alpha and GLUT4 genes in 3T3-L1 adipocytes by tumor necrosis factoralpha. Regulations is coordinate and independent of protein synthesis. J Biol Chem 267: 13580–13584, 1992
Feinstein R, Kanety H, Papa MZ, Lunenfeld B, Karasik A: Tumor necrosis factor-α suppresses insulin-induced tyrosine phosphorylation of insulin receptor and its substrates. J Biol Chem 268: 26055–26058, 1993
Peraldi P, Hotamisligil GS, Buurman WA, White MF, Spiegelman BM: Tumor necrosis factor (TNF)-α inhibits insulin signaling through stimulation of the p55 TNF receptor and activation of sphingomyelinase. J Biol Chem 271: 13018–13022, 1996
Kroder G, Bossenmayer B, Kellerer M, Capp E, Stoyanov B, Muhlhofer A, Berti L, Horikoshi H, Ullrich A, Haring H: Tumor necrosis factor α and hyperglycemia-induced insulin resistance. J Clin Invest 97: 1471–1477, 1996
White MF, Kahn CR: The insulin signaling system. J Biol Chem 269: 1–4, 1994
Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM: 1RS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-α-and obesity-induced insulin resistance. Science 271: 665–668, 1996
Kanety H, Feinstein R, Papa M, Hemi R, Karasik A: Tumor necrosis factor-α-induced phosphorylation of insulin receptor substrate-1 (IRS-1). J Biol Chem 270: 23780–23784, 1995
Kolesnick R, Golde D: The sphingomyelin pathway in tumor necrosis factor and interleukin-1 signaling. Cell 77: 325–328, 1994
Lozano J, Berra E, Municio M, Diaz-Meco M, Dominguez I, Sanz L, Moscat J: Protein kinase C isoform is critical for kappa B-dependent promoter activation by sphingomyelinase. J Biol Chem 269: 19200–19202, 1994
Muller G, Ayoub M, Storz P, Rennecke J, Fabbro D, Pfizenmaier K: PKC ζ is a molecular switch in signal transduction of TNF-α bifunctionally regulated by ceramide and arachidonic acid. EMBO J 14: 1156–1165, 1995
Yao B, Zhang Y, Delikat S, Mathias S, Basu S, Kolesnick R: Phosphorylation of Raf by ceramide-activated protein kinase. Nature 378: 307–310, 1995
Dobrowsky R, Hannun Y: Ceramide stimulates a cytosolic protein Phosphatase. J Biol Chem 267: 5048–5051, 1992
Ofei F, Hurel S, Newkirk J, Sopwith M, Taylor R: Effects of an engineered human anti-TNF-a antibody (CPD571) on insulin sensitivity and glycemic control in patients with NIDDM. Diabetes 45: 881–885, 1996
Boden G, Chen X, Ruiz J, White JV, Rosseti L: Mechanisms of fatty acid-induced inhibition of glucose uptake. J Clin Invest 93: 2438–2446, 1994
Muller HK, Kellerer B, Ermel A, Muhlhofer B, Obermaier-Kusser B, Vogt B, Haring HC: Prevention by protein kinase C inhibitors of glucoseinduced insulin receptor tyrosine kinase resistance in rat fat cells. Diabetes 40: 1440–1448, 1991
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1998 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Peraldi, P., Spiegelman, B. (1998). TNF-α and insulin resistance: Summary and future prospects. In: Srivastava, A.K., Posner, B.I. (eds) Insulin Action. Developments in Molecular and Cellular Biochemistry, vol 24. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-5647-3_18
Download citation
DOI: https://doi.org/10.1007/978-1-4615-5647-3_18
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-7584-5
Online ISBN: 978-1-4615-5647-3
eBook Packages: Springer Book Archive